Pathology: mHCC - 1st line (L1); mHCC - 2nd line (L2);
| mHCC - 1st line (L1) | mHCC - 2nd line (L2) | ||||||
| IMbrave-150, 2020 | CheckMate 459, 2019 | LEAP 002, 0 | ORIENT-32, 2021 | KEYNOTE-240, 2020 | KEYNOTE-394, 2022 | ||
| pembrolizumab plus lenvatinib | 1 | T1 | |||||
| pembrolizumab based treatment | 1 | T1 | |||||
| sintilimab | 1 | T1 | |||||
| atezolizumab plus bevacizumab | 1 | T1 | |||||
| pembrolizumab alone | 1 | T1 | |||||
| nivolumab alone | 1 | T1 | |||||
| lenvatinib | 0 | T0 | |||||
| placebo | 0 | T0 | T0 | ||||
| sorafenib | 0 | T0 | T0 | T0 | |||